New data from Novo Nordisk’s phase 3 trial of an oral, high-dose formulation of semaglutide reinforces its potential as a weight-loss therapy in obesity, but Eli Lilly is
Boehringer Ingelheim and partner Zealand Pharma have reported new clinical data in obesity for their dual glucagon/GLP1 agonist BI 456906, setting up a possible challenge
Seismic Therapeutic has raised $121 million in second-round financing that will be used to take its two lead drugs through early-stage clinical testing.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio